Quoin Secures EMA Orphan Drug Designation For QRX003 In Rare Skin Disorder

Quoin Pharmaceuticals received European Medicines Agency Orphan Drug Designation for QRX003, which is being developed as a potential treatment for Peeling Skin Syndrome, a rare inherited skin disorder with significant unmet medical need. The article text is truncated, so no further details about the designation or its implications are available.